
Access from the University of Nottingham repository:
http://eprints.nottingham.ac.uk/40090/1/EPI-2016-0042.pdf

Copyright and reuse:
The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the University of Nottingham End User licence and may be reused according to the conditions of the licence. For more details see:
http://eprints.nottingham.ac.uk/end_user_agreement.pdf

A note on versions:
The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk
DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis

John R. Glossop¹², Nicola B. Nixon², Richard D. Emes³⁴, Julius Sim⁵, Jon C. Packham¹², Derek L. Mattey¹², William E. Farrell¹, Anthony A. Fryer¹.

¹Institute for Applied Clinical Sciences, Keele University, Guy Hilton Research Centre, Thornburrow Drive, Hartshill, Stoke-on-Trent, Staffordshire, ST4 7QB, UK.
²Haywood Rheumatology Centre, Haywood Hospital, High Lane, Burslem, Stoke-on-Trent, Staffordshire, ST6 7AG, UK.
³School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Sutton Bonington, Leicestershire, LE12 5RD, UK.
⁴Advanced Data Analysis Centre, University of Nottingham, Sutton Bonington Campus, Sutton Bonington, Leicestershire, LE12 5RD, UK.
⁵School of Health and Rehabilitation, Keele University, Staffordshire, ST5 5BG, UK.

Author for correspondence/re-prints: Professor Tony Fryer, Institute for Applied Clinical Sciences, Keele University, Guy Hilton Research Centre, Thornburrow Drive, Hartshill, Stoke-on-Trent, Staffordshire, ST4 7QB, UK.
Tel: +44 (0) 1782 674245
Fax: +44 (0) 1782 747319
E-mail: anthony.fryer@uhnms.nhs.uk
Key words: Disease-modifying antirheumatic drugs (DMARDs); disease activity score with 28 joint counts (DAS28); DNA methylation; Early rheumatoid arthritis; Illumina 450K array; T-lymphocyte; Treatment response.

Funding support: This work was supported by funding from the Haywood Rheumatism Research and Development Foundation.

Acknowledgements: The authors would like to thank the patients who participated in the study. We also thank Janet Turner, Cath Thwaites and Moira Dishman for assistance with the collection of clinical data.

Running footnote: DNA methylation and treatment response in early RA
Abstract

Aims. A proof-of-concept study to explore whether DNA methylation at first diagnosis is associated with response to disease-modifying antirheumatic drugs (DMARDs) in patients with early rheumatoid arthritis (RA).

Patients & Methods. DNA methylation was quantified in T-lymphocytes from 46 treatment-naïve patients using HumanMethylation450 BeadChips. Treatment response was determined at six months using the EULAR response criteria.

Results. Initial filtering identified 21 CpGs that were differentially methylated between responders and non-responders. After conservative adjustment for multiple testing, six sites remained statistically significant, of which four showed high sensitivity and/or specificity (≥75%) for response to treatment. Moreover, methylation at two sites in combination was the strongest factor associated with response (80.0% sensitivity, 90.9% specificity, AUC 0.85).

Conclusions. DNA methylation at diagnosis is associated with DMARD treatment response in early RA.
Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease of autoimmune origin that affects 0.5–1.0% of the adult population [1, 2]. Treatment of patients with centres on the use of a variety of synthetic disease-modifying antirheumatic drugs (DMARDs). Methotrexate is the first-line DMARD of choice for the treatment and management of RA, prescribed as monotherapy or in combination with other DMARDs. Although these agents are efficacious for the treatment of RA [3-5], clinically meaningful responses are not observed in all patients and a significant proportion remain refractory to treatment.

A substantial body of literature supports an important role for epigenetic dysregulation, including of DNA methylation, in the pathogenesis of RA [reviewed in 6-8]. Evidence also suggests that disease modifying agents such as methotrexate may influence DNA methylation [9, 10]. Moreover, methylation status as a potential biomarker associated with response to therapy has been demonstrated in other conditions [11] and proposed for use in RA by several investigators [12, 13]. DNA is methylated through enzymatic conversion of cytosine to methylcytosine; this occurring almost invariably at cytosine-phosphate-guanine sites (CpGs). In the context of promoter-associated sites, methylation is associated with transcriptional repression and gene silencing [14]. In RA, alterations to the DNA methylome are apparent in multiple cell types important in the disease process, including peripheral blood-derived mononuclear cells, lymphocytes and joint-derived fibroblasts. Recently, we were the first to define disease-associated methylation changes that were distinct to individual T- and B-lymphocyte populations [15]. Moreover, we reported methylation differences in these lymphocyte populations in treatment-naïve patients at first RA diagnosis [16]. Whilst providing evidence for a role
in the development of the disease, our findings support DNA methylation profiling at
diagnosis as a potential source of biomarkers for response to treatment in RA.

It is clear that the ability to identify which patients will respond to treatment offers
considerable benefits for the management of RA. For example, it would (i) facilitate
rapid dose-escalation and reduce time to effective response in those likely to be poor
responders to traditional regimens, and (ii) avoid unwanted side-effects in those likely
to show an effective response to lower doses or monotherapy. These benefits are all the
more important given evidence that response to first treatment with disease-modifying
agents is strongly associated with long-term outcome in these patients [17]. The search
for biomarkers associated with response has encompassed demographic and clinical
factors as well as genetic associations and expression profiling of proinflammatory and
other mediators [18-20]. However, no single factor or combination of factors have thus
far proven to be accurate and reliable in determining which patients will respond to
DMARD therapy.

Our aim therefore, in this proof-of-concept study, was to determine whether genome-
wide DNA methylation profiles at first diagnosis are associated with response to
treatment with conventional DMARDs (as determined by improvement in disease
activity using the validated European League Against Rheumatism (EULAR) response
criteria) in a typical population of newly-diagnosed, treatment-naïve patients with RA.
As in our previous work, we examined methylation in purified T-lymphocyte
populations, cells that are instrumental in the disease process and chronic inflammation
[21], and for which relationships with disease activity have recently been described [22-24].
Patients and Methods

Study population

A prospective cohort of 46 Caucasian patients attending the early synovitis clinic at the Haywood Rheumatology Centre in Stoke-on-Trent, UK, and presenting with symptomatic inflammatory arthritis suspected to be RA was recruited. All patients were subsequently classified as having RA, according to the 2010 ACR/EULAR classification criteria, by a consultant rheumatologist [25]. No patients had been treated with DMARDs or biological agents at the time of recruitment. Clinical data collected at baseline included disease activity, erythrocyte sedimentation rate (ESR), rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA). Demographic and clinical characteristics are presented in Table 1. At diagnosis with RA, all patients began treatment with one or more DMARDs (methotrexate, hydroxychloroquine, and sulphasalazine) and the majority received parenteral corticosteroids, solely for the clinical management of RA and as directed by a consultant rheumatologist. Patients were followed for six-months and remained on treatment throughout. The study was approved by the East Midlands (Derby) Research Ethics Committee. All patients provided written informed consent.

Disease activity was determined at recruitment (prior to initiation of DMARD therapy) and after three and six months of treatment using the disease activity score with 28-joint counts (DAS28) [26], though data at three months was excluded from further analysis due to the known short-term effect of corticosteroid treatment on DAS28 scores. DAS28 scores range from 0-10: a score >5.1 indicates high disease activity while one of ≤3.2 denotes low disease activity. Response to treatment was determined at six months
according to the DAS28-based EULAR response criteria [26-28], which evaluate
response in patients with RA based on a composite categorization incorporating both
change in DAS28 from baseline (ΔDAS28) and final absolute DAS28 score.
Specifically, these criteria classify response as ‘good’ (ΔDAS28 >1.2, current DAS28
≤3.2), ‘moderate’ (ΔDAS28 >1.2, current DAS28 >3.2, or ΔDAS28 >0.6–1.2, current
DAS28 ≤5.1) and ‘no’ (ΔDAS28 ≤0.6, or ΔDAS28 >0.6–1.2, current DAS28 >5.1) [28].
According to these criteria, responders were defined as patients with a ‘good’ or
‘moderate’ response to treatment, and non-responders as patients with ‘no’ response to
treatment.

**Isolation of T-lymphocytes**

Fresh peripheral blood samples (35 ml, EDTA) were collected from each patient at
baseline, prior to the initiation of treatment. CD3+ T-lymphocytes were isolated from
mononuclear cell preparations using positive selection with magnetic microbeads
(MACS® Separation System; Miltenyi Biotec). We have previously shown this method
to yield high-purity T-lymphocyte populations (mean ≥ 99%) in RA patients [15].
Genomic DNA was extracted using an AllPrep DNA/RNA/miRNA Universal kit
(Qiagen) and stored at -20°C prior to use.

**Genome-wide DNA methylation profiling**

DNA methylation was quantified at >480,000 CpG sites using the
HumanMethylation450 BeadChip (Illumina Inc.; hereafter referred to as ‘array’).
Details of array design and coverage have been described elsewhere [29]. Genomic
DNA samples (n = 46) were treated with sodium bisulfite using an EZ DNA
Methylation Kit (Zymo Research) and subsequently were hybridized to arrays according to manufacturer recommended protocols, as previously described (performed by Hologic Tepnel Pharma Services, Manchester, UK) [30]. All samples passed stringent internal array quality control, including sample-independent (e.g. staining, hybridization) and sample-dependent (e.g. bisulfite conversion) controls. Methylation at individual CpG sites is reported as a β-value ranging from 0 to 1 (unmethylated to fully methylated, respectively) [29].

**Sodium bisulfite Pyrosequencing**

Array candidates were independently validated by bisulfite Pyrosequencing using a PyroMark Q24 instrument and analysis software (Qiagen), as we have previously described [15, 30]. Briefly, fresh genomic DNA aliquots were sodium bisulfite-converted and amplified using whole genome amplification [30, 31]. Thereafter, Touchdown PCR [32, 33] was used to prepare PCR amplicons containing CpGs of interest. Assay details are provided in Supplementary Table 1.

**Data analysis**

Array data (idat files) were processed and analyzed using the Bioconductor package Minfi [34]. We removed from analysis all CpGs with a detection p-value >0.01 in any one or more of the 46 samples and all probes targeting sites on the X and Y chromosomes (a total of 12,295 CpGs). Data were normalized by Subset-quantile Within Array Normalization (SWAN), as described by Maksimovic et al. [35], and multi-dimensional scaling plots were examined to confirm appropriate adjustment for potential confounding due to batch effects (processing date, array position and slide).
To identify methylation differences associated with treatment response, patients were stratified into responders and non-responders. CpGs showing altered methylation between the two groups were identified using the ‘dmpFinder’ function in Minfi. This function performs an F-test to compare groups and was used with logit-transformed β-values (M-values), as recommended by Du et al. [36]. P-values <0.05 were considered statistically significant and, together with a mean β-value difference ≥0.1 between the groups, were used as an initial screening tool to identify sites displaying differential methylation. Two further filtering steps were subsequently applied to identify differentially methylated CpGs as those sites where: 1) at least two-thirds of non-responders showed a β-value difference ≥0.1 relative to the responder mean; and 2) at least two-thirds of responders displayed a β-value equal to or in excess of the responder mean. Filtering criteria are summarized in Figure 1. We then applied a Bonferroni adjustment at stage 5, based on comparisons conducted using the final 21 CpGs identified. The McNemar test was used to examine the incidence of patients with moderate/high disease activity between baseline and six-months. The association of baseline methylation status with treatment response was determined by calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV), and by examining receiver operating characteristic (ROC) area under the curve (AUC) plots. ROC curves were constructed based on logistic regression analysis with response to treatment categorised as no response versus moderate/good response as described.
above. Analyses were performed using Stata 12.0 (Intercooled; Stata Corporation, TX, USA) and considering p-values <0.05 as statistically significant.
Results

Characteristics of the patients

Table 1 summarizes the demographic and clinical characteristics for the RA patients at recruitment. Most patients (43/46, 93.5%) started treatment with MTX, either as monotherapy or in combination with other DMARDs. The majority of patients (33/46, 71.7%) remained on their indicated starting DMARD regimen throughout the course of the study. Of the remaining patients, all but two introduced or discontinued a single DMARD on one occasion during the six-month follow-up period.

Disease activity and treatment response

Moderate or high disease activity (DAS28 >3.2) was present in 43/46 (93.5%) patients at recruitment (three patients had low disease activity, with DAS28 scores of 2.27, 2.66 and 3.18). After six-months of treatment, 28/46 (60.9%) patients had moderate/high disease activity (p <0.001 vs. baseline, McNemar test), with approximately two-thirds (63.0%) achieving an improvement in DAS28 ≥1.2. Classifying response by the EULAR response criteria, the number of patients achieving a good, moderate and no response to treatment at six-months was 16 (34.8%), 19 (41.3%), and 11 (23.9%), respectively. On this basis, 76.1% (35/46) of patients were classified as responders and the remainder as non-responders. Details of baseline characteristics and six-month treatment regimens for the two groups are presented in Supplementary Table 2.

Relationship between DNA methylation and treatment response

Use of the robust filtering steps described in the Methods section and shown in Figure 1 identified 269 CpGs with a statistically significant difference in mean methylation β-
value ≥0.1 between responders and non-responders. Moreover, for a subset of 21 sites, methylation differences were present in at least two-thirds of the individual patients within each group (full annotation for these 21 sites is provided in Supplementary Table 3). The majority of these sites were hypermethylated in responders (16/21, 76.2%), were linked with a gene (15/21, 71.4%) and were associated with a CpG island and/or the surrounding shores/shelves (13/21, 61.9%).

To refine these sites further, we applied a conservative Bonferroni adjustment for multiple testing, based on the 21 comparisons undertaken. This revealed six CpGs for which the methylation differences between responders and non-responders remained statistically significant (p_adj < 0.05; Supplementary Table 3). For each of these six CpGs, we plotted methylation against treatment response to determine a percentage methylation cut-off that in each case provided the greatest discrimination between patients that responded to treatment and those that did not. Examples of two differentially methylated CpGs are presented in Figure 2. We also calculated the corresponding sensitivity and specificity for each site to assess the association of methylation status with response. Using this approach, and as shown in Table 2, four sites were identified with a sensitivity and/or specificity ≥75% for discrimination between responders and non-responders. Most notably, hypermethylation of CpG-2 and hypomethylation of CpG-3 (shown in Figure 2 and validated by Pyrosequencing in Supplementary Figure 1) each demonstrated a sensitivity and PPV of approximately 90%, although the corresponding specificity and NPV were lower (63.6% and 70.0%, and 63.6% and 63.6%, for CpG-2 and CpG-3, respectively). Using ROC curve analysis
to further evaluate the association with response, CpG-2 and CpG-3 also demonstrated the highest AUC values (0.78 and 0.76, respectively).

**Combinations of CpGs associated with treatment response**

Focusing on the four sites identified above, we next examined the ability to discriminate between responders and non-responders for each of the six possible pairs of sites. The combination of hypermethylation of CpG-2 and hypomethylation of CpG-3 demonstrated the best overall performance with a sensitivity of 80.0% and specificity of 90.9% (Table 2). As shown in Figure 3, 28 of 29 patients with this combination were responders (14 good and 14 moderate response; right chart, Figure 3). In contrast, all four patients failing to satisfy either cut-off were non-responders (left chart, Figure 3). The strength of the association of the CpG-2 + CpG-3 combination with response was also reflected in a ROC AUC of 0.85 (95% confidence interval [CI] 0.71, 0.94).
Discussion

This is the first study to examine the link between DNA methylation and first-line treatment response in RA. Using a prospective cohort of patients recruited at first diagnosis and prior to the initiation of treatment, our data indicate that baseline DNA methylation levels for a discrete subset of sites are significantly associated with response to treatment with disease-modifying agents. The methylation status at two specific sites assessed in combination, and which independently were associated with response, proved to be the strongest factor associated with treatment response.

Since early, effective intervention in RA reduces disease activity and inflammation, and improves long-term outcome [37-40], identification of baseline factors associated with treatment response has been a priority. However, examination of a broad range of clinical, molecular and genetic factors has not produced definitive biomarkers [18, 19]. Our findings now provide the first evidence that epigenetic profiling, in this case of DNA methylation, may have significant value in identifying which patients with RA may respond to first-line DMARD treatment. Furthermore, DNA methylation is an attractive biomarker since it is typically stable over time, is minimally affected by short-term stimuli and is readily measured [12]. The potential utility of methylation profiling is further supported by a very recently reported association between differential DNA methylation and response to second-line anti-TNF therapy in RA [41].

We were unable to formally examine the independence of the CpG-2 + CpG-3 association with treatment response in this proof-of-concept study. However, a preliminary assessment using our data suggested that it was independent of baseline
clinical variables including disease activity, autoantibodies and systemic inflammatory markers, which individually did not appear to be associated with response. This would be in agreement with the main body of literature, which indicates that ESR, RF and ACPA are not independently associated with response to methotrexate and/or other DMARDs [reviewed in 18]. Although not reported by all studies [42], evidence does indicate that male sex is associated with a better response to methotrexate [43-45]. Our data suggest a possible trend towards better response in males (p <0.1), which may reflect treatment with methotrexate for over 90% of the patients studied.

The CpG-2 + CpG-3 combination, which we identified as the strongest independent factor associated with treatment response, comprises sites in ADAMTSL2 (CpG-2), a disintegrin and metalloproteinase with thrombospondin motif-like protein, and in BTN3A2 (CpG-3), a butyrophilin family member. Although the function of ADAMTSL2 has not been fully determined, evidence supports a role in the regulation of transforming growth factor-β (TGF-β) [46]. TGF-β is a pleiotropic cytokine with important immunoregulatory functions [47, 48], which is implicated in RA synovial pathology [49]. Butyrophilins are transmembrane proteins that share structural similarities with B7 co-stimulatory molecules and are emerging as novel regulators of T-lymphocyte function and immune responses [50, 51].

We focused on DNA methylation factors associated with response in the context of DMARD treatment strategies that reflected standard clinical practice. Both responder and non-responder groups included patients receiving methotrexate monotherapy and patients receiving combination therapy, the proportions of which were not significantly
different either at baseline or at six-months follow-up (Supplementary Table 2).

Importantly, methylation at two CpGs in combination was strongly associated with treatment response despite the limited variation in treatment regimens, supporting its potential utility as a marker of response at diagnosis in a real-world clinical setting.

Furthermore, we purposefully used the EULAR criteria as the response measure in this study as these are universally accepted and encompass both improvement in disease activity over time and end-point disease activity. Reassuringly, the proportion of responders in this study is consistent with previous reports using these criteria [44, 52].

By quantifying methylation at baseline, we are also able to exclude potential confounding associated with DMARDs, including methotrexate, an impact of which on methylation has been suggested by several groups [9,10,53,54].

Although our proof-of-concept study is the first of its kind in RA, a limitation of our work was the relatively small number of patients that we were able to recruit. In an attempt to address this, we used a number of sequential filtering steps to identify sites differentially methylated between responders and non-responders to treatment.

Furthermore, for the two CpGs comprising the strongest biomarker associated with response, we validated the array data by also quantifying methylation using an independent method (Pyrosequencing). This significantly reduces the risk of type I errors associated with genome-wide approaches. However, we recognise that an important next step will be to confirm our findings and determine the true predictive value of this biomarker in larger, independent patient cohorts.
Conclusions

In conclusion, we report the identification of a novel DNA methylation combination that is associated with response to treatment with conventional disease-modifying drugs in newly diagnosed patients with RA. Whilst our findings will require verification in larger, independent early RA cohorts, they provide the first evidence to support epigenetic profiling as a novel approach to identifying biomarkers associated with response to DMARD therapy. Ultimately, this has the potential to inform clinical management and patient care, towards the goal of a stratified, personalized medicine approach to treatment.
Executive Summary

Background

- Newly diagnosed patients with rheumatoid arthritis (RA) demonstrate variability of response to treatment with disease-modifying antirheumatic drugs (DMARDs).
- To date, no definitive biomarkers associated with response have been identified.
- This proof-of-concept study explored whether DNA methylation at first diagnosis is associated with response to treatment with DMARDs in patients with treatment-naïve early RA.

Patients & Methods

- HumanMethylation450 BeadChips were used to quantify genome-wide DNA methylation at diagnosis in T-lymphocytes from 46 treatment-naïve patients with early RA.
- Response to DMARD treatment was determined at six months using the DAS28-based EULAR response criteria. Sensitivity, specificity and receiver operating characteristic AUC data were used to assess associations of baseline methylation with treatment response.

Results

- At six-months, the numbers of patients achieving a good/moderate/no response to treatment were 16/19/11 (35/41/24%), respectively.
- Array analysis identified 21 CpGs displaying methylation differences between responders and non-responders, of which four statistically significant sites (p_{adj} < 0.05, Bonferroni) showed high sensitivity and/or specificity ≥75% for treatment response.
Methylation at two individual sites in combination (cg0301849 and cg14345882) was the strongest factor associated with response, with 80.0% sensitivity and 90.9% specificity (AUC 0.85). 28 of 29 patients with this combination were responders.

Conclusions

DNA methylation of a novel CpG combination is associated with treatment response at first diagnosis in early RA patients prior to commencing treatment with DMARDs.

These findings provide the first evidence to support epigenetic profiling as a novel approach to identifying biomarkers associated with DMARD treatment response in RA. This may ultimately have the potential to inform clinical management and patient care.
References

Articles of interest have been highlighted as:

* of interest


**First DNA methylation array study in newly diagnosed RA patients naïve for treatment with disease-modifying antirheumatic drugs**


**Comprehensive review article discussing current evidence for predicting response to disease modifying drugs in RA.**


*Association between differential DNA methylation and response to second-line anti-TNF therapy in RA.*


Financial disclosure/Acknowledgements

The authors would like to thank the patients who participated in the study. We also thank Janet Turner, Cath Thwaites and Moira Dishman for assistance with the collection of clinical data. This work was supported by funding provided by Haywood Rheumatism Research and Development Foundation. The authors have no conflict of interest to disclose and have no relevant affiliations with or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. The authors did not receive any writing assistance in the preparation of the manuscript.
Figure legends

Figure 1. Filtering criteria for identification of CpGs differentially methylated at baseline (pre-treatment) between treatment responders and non-responders in patients with early RA. The starting number of CpGs indicated (482,421) is the total number of CpGs on the methylation array platform. Following initial processing (step 1), data were normalized using SWAN [35], implemented in the Bioconductor package Minfi [34]. Numbers in the figure indicate the number of CpGs remaining at each successive step.

Abbreviations: RA, rheumatoid arthritis; SWAN, subset-quantile within array normalization.

Figure 2. Pre-treatment methylation status discriminates responders and non-responders in patients with early RA. In (A) CpG-2 (cg03018489) and (B) CpG-3 (cg14345882), non-responders (n = 11) and responders (n = 35) are depicted by open circles and filled triangles, respectively, and where responders are divided into those showing a moderate (centre, n = 19) and good (right, n = 16) response to treatment. Good, moderate and no response categories are defined in the EULAR response criteria [23-25]. The horizontal dashed line indicates the methylation cut-off for distinguishing between responders and non-responders, and the short horizontal bar in each group indicates the mean value.

Abbreviations: RA, rheumatoid arthritis; EULAR, European League Against Rheumatism).
Figure 3. Pre-treatment methylation status at two CpG sites in combination is associated with response to treatment in patients with early RA patients. For CpG-2 (cg03018489) and CpG-3 (cg14345882) methylation status was defined as hypermethylated (above) or hypomethylated (below) relative to a cut-off of 60% and 20%, respectively. Shown on the x-axis are the four possible methylation combinations, with methylation status of CpG-2 given first and of CpG-3 given second, as indicated (the two combinations in which only one CpG satisfied the cut-off value are grouped together (centre chart)). Each chart depicts the proportion of patients achieving a good (white), moderate (striped) and no response (dark grey) to treatment, stratified by methylation status for the CpG-2/CpG-3 combination.

Abbreviations: RA, rheumatoid arthritis; Hypo, hypomethylated; Hyper, hypermethylated.

Supplementary Figure 1. Technical validation by bisulfite pyrosequencing of baseline methylation status for two CpGs differentially methylated between responders and non-responders in patients with early RA. In both (A) CpG-2 (cg03018489) and (C) CpG-3 (cg14345882), responders (n = 35) and non-responders (n = 11) are depicted by triangles and circles respectively. The short red horizontal bar shown in each group indicates the mean value. For each CpG, methylation values are shown for the array (filled symbols; left) and Pyrosequencing (open symbols; right). Bland-Altman plots in (B) CpG-2 (cg03018489) and (D) CpG-3 (cg14345882) show the agreement between % methylation levels as determined by 450K array and pyrosequencing analysis. Each point represents an individual patient. Shown by horizontal lines are the mean difference between the methods (bias) and the upper and
lower boundaries of the 95% limits of agreement (± 1.96 SD). The intraclass correlation coefficient between the methods is 0.963 for CpG-2, and 0.690 for CpG-3.

Abbreviations: RA, rheumatoid arthritis; 450K, HumanMethylation450 BeadChip

Supplementary Table 1. Assay details for candidate CpGs/genes interrogated by bisulfite Pyrosequencing.*

*Further information that is not included here is available upon request.

†The prefix 'b-' denotes biotin labeling at the 5' end.

‡The sequence indicated is post-bisulfite conversion. Letters 'Y' and 'R' denote the cytosine of the CpG site interrogated by the assay ('Y' and 'R' refer to sequencing in the forward and reverse orientation, respectively).

Abbreviations: bp, base pairs.

Supplementary Table 2. Baseline demographic and clinical characteristics in early RA patients who responded and did not respond to DMARD treatment at 6-months follow-up.

* Mann-Whitney U test (continuous variables) or Fisher’s exact test (categorical), as appropriate.

† data unavailable for two patients.

‡ data unavailable for one patient.

§ 26/45 (57.8%) patients were positive for ACPA/ RF (data unavailable for one patient).

¥ The total number of patients starting treatment with a given DMARD, whether received as monotherapy or in combination with other DMARDs.

* One further patient received monotherapy with hydroxychloroquine.
One patient was not receiving DMARD treatment.

Abbreviations: RA, rheumatoid arthritis; DMARDs, disease-modifying anti-rheumatic drugs; RF, rheumatoid factor; ACPA, anti-citrullinated peptide antibodies; DAS28, disease activity score with 28-joint count; ESR, erythrocyte sedimentation rate.

Supplementary Table 3. Complete list and annotation for the 21 CpGs identified as differentially methylated at baseline (pre-treatment) between responders and non-responders in patients with early RA patients.*

*Bold blue font indicates CpGs with statistically significant (p <0.05, Bonferroni-adjusted) differences in methylation between responders and non-responders. The dashed horizontal line between rows 18 and 19 separates CpGs that were hypermethylated (above) and hypomethylated (below) in responders relative to non-responders.

†The 'dmpFinder' function in Minfi [34] was used to calculate F-test p-values.

Abbreviations: RA, rheumatoid arthritis.
1. Remove CpGs:
   1) with a detection p-value ≥ 0.01;
   2) located on the XY chromosomes

Data normalisation

2. Retain CpGs with a significant (p < 0.05) difference in mean \( \beta \)-value between Non-responders and Responders

3. Retain CpGs with a difference in mean \( \beta \)-value ≥ 0.1 between Non-responders and Responders

4. Retain CpGs where ≥ 7 of 11 (64%) Non-responders show a \( \beta \)-value difference ≥ 0.1 relative to the Responder mean

5. Retain CpGs where ≥ 23 of 35 (66%) Responders have a \( \beta \)-value equal to or in excess of the Responder group mean

A. Methylation \( \beta \)-value vs. Response

B. Methylation \( \beta \)-value vs. Response
CpG-2 + CpG-3 methylation
A 100

Methylation (%)

0

Responder
Non-responder

450K array

Pyrosequencing

CpG-2

B

0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0

Mean (array and pyrosequencing)

0.0

-10.0

-20.0

Difference (array − pyrosequencing)

+1.96 SD

Mean

-1.96 SD

CpG-2

continued over…
Table 1. Demographic and clinical characteristics at baseline for the cohort of 46 treatment-naïve patients with early RA.

<table>
<thead>
<tr>
<th>Number</th>
<th>46</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female, No. (%)</td>
<td>16/30 (34.8/65.2)</td>
</tr>
<tr>
<td>Age, mean ± SD (years)</td>
<td>57.7 ± 13.9</td>
</tr>
<tr>
<td>RF positive, No. (%) †§</td>
<td>23 (52.3)</td>
</tr>
<tr>
<td>ACPA positive, No. (%) ‡§</td>
<td>22 (48.9)</td>
</tr>
<tr>
<td>DAS28, mean ± SD</td>
<td>5.29 ± 1.4</td>
</tr>
<tr>
<td>ESR, mean ± SD</td>
<td>30.1 ± 23.7</td>
</tr>
<tr>
<td>Corticosteroids, No. (%)</td>
<td>45 (97.8)</td>
</tr>
<tr>
<td>Starting DMARD, No. (%) ¥</td>
<td></td>
</tr>
<tr>
<td>Methotrexate (MTX)</td>
<td>43 (93.5)</td>
</tr>
<tr>
<td>Hydroxychloroquine (HCQ)</td>
<td>29 (63.0)</td>
</tr>
<tr>
<td>Sulphasalazine (SSZ)</td>
<td>23 (50.0)</td>
</tr>
<tr>
<td>Starting treatment regimens, No. (%)</td>
<td></td>
</tr>
<tr>
<td>Monotherapy (MTX)*</td>
<td>15 (32.6)</td>
</tr>
<tr>
<td>Triple therapy (MTX+HCQ+SSZ)</td>
<td>20 (43.5)</td>
</tr>
<tr>
<td>Dual therapy (two of MTX, HCQ and SSZ)</td>
<td>10 (21.7)</td>
</tr>
</tbody>
</table>

† of 44 patients (data unavailable for two patients).
‡ of 45 patients (data unavailable for one patient).
§ 26/45 (57.8%) patients were positive for ACPA/ RF (data unavailable for one patient).
¥ The total number of patients starting treatment with a given DMARD, whether received as monotherapy or in combination with other DMARDs.
* One further patient started monotherapy with hydroxychloroquine.
Table 2. Association of baseline methylation status with treatment response in patients with early RA.*

<table>
<thead>
<tr>
<th>pG ID</th>
<th>Methylation in responders:</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
<th>ROC AUC (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual sites</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pG-1 (cg07225509)</td>
<td>Hyper</td>
<td>77.1</td>
<td>72.7</td>
<td>90.0</td>
<td>50.0</td>
<td>0.75 (0.59, 0.86)</td>
</tr>
<tr>
<td>pG-2 (cg03018489)</td>
<td>Hyper</td>
<td>91.4</td>
<td>63.6</td>
<td>88.9</td>
<td>70.0</td>
<td>0.78 (0.64, 0.89)</td>
</tr>
<tr>
<td>pG-3 (cg14345882)</td>
<td>Hypo</td>
<td>88.6</td>
<td>63.6</td>
<td>88.6</td>
<td>63.6</td>
<td>0.76 (0.61, 0.87)</td>
</tr>
<tr>
<td>pG-4 (cg23974730)</td>
<td>Hypo</td>
<td>82.9</td>
<td>63.6</td>
<td>87.9</td>
<td>53.9</td>
<td>0.73 (0.59, 0.86)</td>
</tr>
<tr>
<td>Combinations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pG-1 + CpG-2</td>
<td>Hyper/Hyper</td>
<td>71.4</td>
<td>90.9</td>
<td>96.2</td>
<td>50.0</td>
<td>0.81 (0.66, 0.91)</td>
</tr>
<tr>
<td>pG-1 + CpG-3</td>
<td>Hyper/Hypo</td>
<td>65.7</td>
<td>81.8</td>
<td>92.0</td>
<td>42.9</td>
<td>0.74 (0.59, 0.86)</td>
</tr>
<tr>
<td>pG-1 + CpG-4</td>
<td>Hyper/Hypo</td>
<td>60.0</td>
<td>90.9</td>
<td>95.5</td>
<td>41.7</td>
<td>0.75 (0.61, 0.87)</td>
</tr>
<tr>
<td>pG-2 + CpG-3</td>
<td>Hyper/Hypo</td>
<td><strong>80.0</strong></td>
<td><strong>90.9</strong></td>
<td><strong>96.6</strong></td>
<td><strong>58.8</strong></td>
<td><strong>0.85 (0.71, 0.94)</strong></td>
</tr>
<tr>
<td>pG-2 + CpG-4</td>
<td>Hyper/Hypo</td>
<td>77.1</td>
<td>72.7</td>
<td>90.0</td>
<td>50.0</td>
<td>0.75 (0.59, 0.86)</td>
</tr>
<tr>
<td>pG-3 + CpG-4</td>
<td>Hypo/Hypo</td>
<td>74.3</td>
<td>90.9</td>
<td>96.3</td>
<td>52.6</td>
<td>0.83 (0.69, 0.92)</td>
</tr>
</tbody>
</table>

*Of the six CpGs identified as significantly differentially methylated between responders and non-responders (see main text), shown are the four CpGs with a sensitivity and/or specificity ≥75% and that showed most promise for discriminating between responders and non-responders. Also shown are the six possible CpG pairs derived from these four sites. All individual sites and combinations shown were significantly associated with treatment response (p < 0.05, Fisher’s exact test). The CpG-2 + CpG-3 combination displayed the best overall performance (p < 0.001; bold font).